Article Type
Changed
Tue, 08/23/2022 - 14:44

Key clinical point: A starch‐ and sucrose‐reduced diet (SSRD) led to a significant shift in the gut microbiota, which correlated with reduced gastrointestinal (GI) symptoms, in patients with irritable bowel syndrome (IBS).

 

Major finding: A significant shift in beta-diversity was observed in the intervention group (P < .001), along with a significant increase in the abundance of Proteobacteria (P  =  .0036), Lentisphaerae (P  =  .0038), and Cyanobacteria (P  =  .038) and a decrease in Bacteroidetes (P < .001). The abundance of Proteobacteria correlated positively (P  =  .0016) and Bacteroidetes negatively (P  =  .0017) with reduced total GI symptoms.

 

Study details: This study included 105 patients with IBS who were randomly assigned to receive a 4‐week SSRD intervention (n = 80) or habitual (n = 25) diet.

 

Disclosures: This study was partially funded by the Skåne University Hospital Foundation, Dir Albert Påhlsson Foundation, and others. The authors declared no conflicts of interest.

 

Source: Nilholm C et al. A starch- and sucrose-reduced dietary intervention in irritable bowel syndrome patients produced a shift in gut microbiota composition along with changes in phylum, genus, and amplicon sequence variant abundances, without affecting the micro-RNA levels. United European Gastroenterol J. 2022;10(4):363-375 (Apr 28). Doi: 10.1002/ueg2.12227

 

Publications
Topics
Sections

Key clinical point: A starch‐ and sucrose‐reduced diet (SSRD) led to a significant shift in the gut microbiota, which correlated with reduced gastrointestinal (GI) symptoms, in patients with irritable bowel syndrome (IBS).

 

Major finding: A significant shift in beta-diversity was observed in the intervention group (P < .001), along with a significant increase in the abundance of Proteobacteria (P  =  .0036), Lentisphaerae (P  =  .0038), and Cyanobacteria (P  =  .038) and a decrease in Bacteroidetes (P < .001). The abundance of Proteobacteria correlated positively (P  =  .0016) and Bacteroidetes negatively (P  =  .0017) with reduced total GI symptoms.

 

Study details: This study included 105 patients with IBS who were randomly assigned to receive a 4‐week SSRD intervention (n = 80) or habitual (n = 25) diet.

 

Disclosures: This study was partially funded by the Skåne University Hospital Foundation, Dir Albert Påhlsson Foundation, and others. The authors declared no conflicts of interest.

 

Source: Nilholm C et al. A starch- and sucrose-reduced dietary intervention in irritable bowel syndrome patients produced a shift in gut microbiota composition along with changes in phylum, genus, and amplicon sequence variant abundances, without affecting the micro-RNA levels. United European Gastroenterol J. 2022;10(4):363-375 (Apr 28). Doi: 10.1002/ueg2.12227

 

Key clinical point: A starch‐ and sucrose‐reduced diet (SSRD) led to a significant shift in the gut microbiota, which correlated with reduced gastrointestinal (GI) symptoms, in patients with irritable bowel syndrome (IBS).

 

Major finding: A significant shift in beta-diversity was observed in the intervention group (P < .001), along with a significant increase in the abundance of Proteobacteria (P  =  .0036), Lentisphaerae (P  =  .0038), and Cyanobacteria (P  =  .038) and a decrease in Bacteroidetes (P < .001). The abundance of Proteobacteria correlated positively (P  =  .0016) and Bacteroidetes negatively (P  =  .0017) with reduced total GI symptoms.

 

Study details: This study included 105 patients with IBS who were randomly assigned to receive a 4‐week SSRD intervention (n = 80) or habitual (n = 25) diet.

 

Disclosures: This study was partially funded by the Skåne University Hospital Foundation, Dir Albert Påhlsson Foundation, and others. The authors declared no conflicts of interest.

 

Source: Nilholm C et al. A starch- and sucrose-reduced dietary intervention in irritable bowel syndrome patients produced a shift in gut microbiota composition along with changes in phylum, genus, and amplicon sequence variant abundances, without affecting the micro-RNA levels. United European Gastroenterol J. 2022;10(4):363-375 (Apr 28). Doi: 10.1002/ueg2.12227

 

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: IBS September 2022
Gate On Date
Wed, 06/29/2022 - 14:30
Un-Gate On Date
Wed, 06/29/2022 - 14:30
Use ProPublica
CFC Schedule Remove Status
Wed, 06/29/2022 - 14:30
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article